# FDA recall D-0720-2021

> **Eli Lilly & Company** · Class II · drug recall initiated 2021-06-29.

## Product

Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01

## Reason for recall

cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

## Distribution

OH, MS, IN

## Key facts

- **Recall number:** D-0720-2021
- **Recalling firm:** Eli Lilly & Company
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2021-06-29
- **Report date:** 2021-08-18
- **Termination date:** 2023-07-29

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Indianapolis, IN, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0720-2021

## Citation

> AI Analytics. FDA recall D-0720-2021. Retrieved 2026-07-18 from https://api.ai-analytics.org/recall/D-0720-2021. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*